Strictosidine glucosidase (SGD) from Catharanthus roseus catalyzes the deglycosylation of strictosidine, an intermediate from which thousands of monoterpene indole alkaloids are derived. The steady state kinetics of SGD with a variety of strictosidine analogs revealed the substrate preferences of this enzyme at two key positions of the strictosidine substrate. Additionally, SGD from C. roseus turns over both strictosidine and its stereoisomer vincoside, indicating that although this enzyme prefers the naturally occurring diastereomer, the enzyme is not completely diastereoselective. The implications of the substrate specificity of SGD in metabolic engineering efforts of C. roseus are highlighted.
Monoterpene indole alkaloids (MIA) are a large class of pharmaceutically valuable and structurally complex natural products. 1 Directed biosynthesis studies have shown that the MIA pathway can produce a variety of "unnatural" alkaloids by utilizing non-natural substrate analogs. 2 This inherent flexibility suggests that MIA biosynthesis could provide a robust platform for metabolic engineering. However, not all substrate analogs are likely to be incorporated into the pathway with equal efficiency. If substrate specificity of individual biosynthetic enzymes correlates with rate limiting steps in vivo, then enzymes having a low catalytic efficiency for a non-natural substrate could be reengineered to improve turnover of the analog. 3 Therefore, evaluation of enzyme substrate specificity is critical for biosynthetic engineering efforts. In MIA biosynthesis, the central biosynthetic precursor strictosidine 1 is deglycosylated by strictosidine glucosidase (SGD) to yield a reactive intermediate that rearranges to form the wide variety of MIA (Scheme 1). 4 Here we evaluate the substrate specificity of SGD from Catharanthus roseus with a variety of strictosidine analogs to determine whether SGD could act as a bottleneck in the production of novel alkaloids from unnatural strictosidine analogs.
SGD was assayed with strictosidine analogs 2-9 (Table 1) . 5-8 An HPLC assay was used to monitor both strictosidine disappearance and deglycosylated product formation. Since all kinetic data appeared to fit a sigmoidal rather than a Michaelis-Menten curve, kinetic constants were obtained from a sigmoidal fit to the data ( Figure 1 ). 9,10 SGD from C. roseus has been reported to form aggregates consisting of 4 to 12 monomers; 4a although a sigmoidal fit has not been previously reported for C. roseus SGD, the oligomeric state of the enzyme is compatible with the cooperative mechanism suggested by the sigmoidal curve.
The catalytic efficiencies (V max /K 0.5 ) of indole substituted strictosidine derivatives 2-9 varied by less than an order of magnitude from the naturally occurring strictosidine 1. Strictosidine analogs with methyl groups in the 9, 10, 11, and 12 positions (compounds 2-5) demonstrated that steric effects did not disrupt enzyme activity dramatically. Not surprisingly, replacement of methyl groups with larger methoxy substituents (compounds 6, 7) resulted in a small increase in the K 0.5 values. Electronic perturbations did not appear to impact the turnover profoundly; catalytic efficiencies of fluorinated strictosidine analogs (8, 9) did not vary significantly from 1.
The recently reported crystal structure of SGD from Rauwolfia serpentina (PDB code 2JF6) indicates that whereas the glucose moiety of 1 is buried within the enzyme active site, the indole portion of strictosidine points toward the surface of the enzyme. 11 The results of these substrate specificity studies suggest that the active site of SGD has not evolved to discriminate against substitutions on the indole ring. Notably, 5 methyl and 6 methyl tryptamine are not turned over by the enzyme strictosidine synthase (Scheme 1) to form strictosidine analogs 3 and 4, respectively. 5 The specificity of the early stages of the MIA pathway therefore appears to be controlled in large part by strictosidine synthase and not by SGD. Any significant differences observed in incorporation of indole-substituted tryptamine substrates into alkaloid products are not likely to be due to the substrate specificity of SGD.
Whereas the modestly sized indole substituents had a moderate effect on SGD catalysis, replacement of the methyl ester of strictosidine with the significantly larger pentynyl ester 12 (compound 10 , Figure 2 ) resulted in a significant decrease in turnover by SGD. No formation of deglycosylated product was observed under the assay conditions used for strictosidine analogs 2-9, although deglycosylation was observed when the SGD concentration was increased from approximately 0.6 nM to 50 µM. The ester appears to be positioned more deeply in the interior of SGD compared to the indole moiety, 11 and steric clashes of the pentynyl group with the surrounding enzyme residues may impede effective catalysis. Mutation of SGD may improve turnover of this substrate.
Notably, the slow turnover rate of 10 parallels the results of feeding studies in which C. roseus hairy root cultures were grown in the presence of the precursor to 10, the pentynyl ester of secologanin. In these feeding studies, 3a,12 a significant accumulation of pentynyl strictosidine 10 was observed, a result consistent with slow deglycosylation of 10 by SGD (Figure 3 , black trace). Therefore, the enzyme substrate specificity can predict bottlenecks in precursor directed biosynthesis. Despite slow deglycosylation by SGD, 10 is nevertheless converted by C. roseus into several downstream alkaloid products; one alkaloid (serpentine) is shown in Figure 3 (red trace). 12 The production levels of these alkaloids could be expected to increase further if a reengineered variant of SGD that more effectively deglycosylates 10 is incorporated into the MIA pathway.
Strictosidine synthase, the enzyme that forms strictosidine 1 from tryptamine and secologanin (Scheme 1), is absolutely stereoselective. The vincoside diastereomer 11 is not formed enzymatically in any known MIA pathway ( Figure 2 ). 1 Although SGD from Rauwolfia serpentina does not turn over the vincoside diastereomer 4b we observed that the C. roseus enzyme does in fact turn over the "non-natural" vincoside 13 as evidenced by an LC-MS assay and a glucose detection assay. 14 Steady state kinetic constants were not obtained for this substrate because vincoside 11 spontaneously formed the lactam 12 during the course of the assay, thereby complicating kinetic analysis. 15 However, the rate of deglycosylation of 11 appeared to be qualitatively slower than that of strictosidine 1. Inspection of the SGD sequence from R. serpentina, which has 70% amino acid identity with C. roseus glucosidase, 4 did not reveal any obvious differences in the strictosidine binding site, 11 so the structural basis for the difference in diastereoselectivity between the two enzymes remains to be determined. SGD catalyzes deglycosylation of strictosidine analogs containing indole substituents at relatively high catalytic efficiencies. In contrast, a significant decrease in catalysis was noted after the methyl ester of strictosidine was replaced with a pentynyl ester (compound 10), a result consistent with accumulation of 10 in feeding studies. Despite the slow turnover of 10 by SGD, 10 is nevertheless converted by C. roseus in vivo into several downstream alkaloid products. 12 We envision that the levels of these alkaloids will increase if a reengineered variant of SGD that more effectively deglucosylates 10 is incorporated into the MIA pathway. Surprisingly, SGD from C. roseus appears to turnover vincoside, the diastereomer of strictosidine, indicating that the stereoselectivity of the MIA pathway is not maintained by SGD.
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